WEKO3
アイテム
{"_buckets": {"deposit": "006e9f42-58cb-4e1c-a152-d89a76a4d55b"}, "_deposit": {"created_by": 2, "id": "5457", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "5457"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00005457", "sets": ["11"]}, "author_link": ["23251", "23250", "23254", "23256", "23252", "23249", "23257", "23255", "23248", "23253"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-05-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "345", "bibliographicPageStart": "340", "bibliographicVolumeNumber": "30", "bibliographic_titles": [{"bibliographic_title": "Journal of Ocular Pharmacology and Therapeutics"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (TaprosR: tafluprost) has been reduced to balance corneal safety and preservative effectiveness (old formulation: 0.01%; new formulation: 0.001%). However, no reports have been published on its clinical effect. Therefore, we conducted a clinical research study to compare the safety of BAK-reduced tafluprost on the ocular surface with other prostaglandin ophthalmic solutions. Methods: This clinical study included 28 glaucoma patients (28 eyes) with a treatment history of latanoprost ophthalmic solution (XalatanR) or travoprost ophthalmic solution (Travatan Z R), who presented with corneal epithelial disorders. The subjects were switched to BAK-reduced tafluprost, and its effect on the ocular surface was examined after 1 and 2 months of treatment [using fluorescein staining score, hyperemia, tear film breakup time, and intraocular pressure (IOP) lowering]. Results: In all analyzed subjects (N=27), the fluorescein staining score was significantly improved after switching to BAK-reduced tafluprost (P\u003c0.0001). Conversely, the IOP-lowering effect was not notably changed. The subjects switched from latanoprost (n=10) showed significant improvement in fluorescein staining score (P\u003c0.05) as well as in IOP lowering (P\u003c0.01). The subjects switched from travoprost (n=17) also showed significant improvement in fluorescein staining score (P\u003c0.001), but without a significant change in IOP lowering. Conclusions: Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect, but also for its good corneal safety profile.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Journal of Ocular Pharmacology and Therapeutics, 30(4), pp.340-345; 2014", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Mary Ann Liebert Inc."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1089/jop.2013.0132", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "This is a copy of an article published in the Journal of Ocular Pharmacology and Therapeutics c 2014 copyright Mary Ann Liebert, Inc.; Journal of Ocular Pharmacology and Therapeutics is available online at: http://online.liebertpub.com."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "10807683", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "15577732", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kumagami, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "23248", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakiyama, Harumi"}], "nameIdentifiers": [{"nameIdentifier": "23249", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kusano, Mao"}], "nameIdentifiers": [{"nameIdentifier": "23250", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kajiyama, Ayano"}], "nameIdentifiers": [{"nameIdentifier": "23251", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miura, Yoko"}], "nameIdentifiers": [{"nameIdentifier": "23252", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uematsu, Masafumi"}], "nameIdentifiers": [{"nameIdentifier": "23253", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoneda, Ai"}], "nameIdentifiers": [{"nameIdentifier": "23254", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kurihara, Junko"}], "nameIdentifiers": [{"nameIdentifier": "23255", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuma, Kiyoshi"}], "nameIdentifiers": [{"nameIdentifier": "23256", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kitaoka, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "23257", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JCPT30_340.pdf", "filesize": [{"value": "147.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 147800.0, "url": {"label": "JCPT30_340.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/5457/files/JCPT30_340.pdf"}, "version_id": "ba196390-2d31-4cdd-8486-7706e359b07d"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Comparison of Corneal Safety and Intraocular Pressure?Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Comparison of Corneal Safety and Intraocular Pressure?Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions"}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/34534", "pubdate": {"attribute_name": "公開日", "attribute_value": "2014-07-15"}, "publish_date": "2014-07-15", "publish_status": "0", "recid": "5457", "relation": {}, "relation_version_is_last": true, "title": ["Comparison of Corneal Safety and Intraocular Pressure?Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions"], "weko_shared_id": -1}
Comparison of Corneal Safety and Intraocular Pressure?Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions
http://hdl.handle.net/10069/34534
http://hdl.handle.net/10069/34534e11c4a63-1b9c-4654-a1a0-991c41b911a0
名前 / ファイル | ライセンス | アクション |
---|---|---|
JCPT30_340.pdf (147.8 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2014-07-15 | |||||
タイトル | ||||||
タイトル | Comparison of Corneal Safety and Intraocular Pressure?Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kumagami, Takeshi
× Kumagami, Takeshi× Wakiyama, Harumi× Kusano, Mao× Kajiyama, Ayano× Miura, Yoko× Uematsu, Masafumi× Yoneda, Ai× Kurihara, Junko× Suzuma, Kiyoshi× Kitaoka, Takashi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: The benzalkonium chloride (BAK) content of tafluprost ophthalmic solution (TaprosR: tafluprost) has been reduced to balance corneal safety and preservative effectiveness (old formulation: 0.01%; new formulation: 0.001%). However, no reports have been published on its clinical effect. Therefore, we conducted a clinical research study to compare the safety of BAK-reduced tafluprost on the ocular surface with other prostaglandin ophthalmic solutions. Methods: This clinical study included 28 glaucoma patients (28 eyes) with a treatment history of latanoprost ophthalmic solution (XalatanR) or travoprost ophthalmic solution (Travatan Z R), who presented with corneal epithelial disorders. The subjects were switched to BAK-reduced tafluprost, and its effect on the ocular surface was examined after 1 and 2 months of treatment [using fluorescein staining score, hyperemia, tear film breakup time, and intraocular pressure (IOP) lowering]. Results: In all analyzed subjects (N=27), the fluorescein staining score was significantly improved after switching to BAK-reduced tafluprost (P<0.0001). Conversely, the IOP-lowering effect was not notably changed. The subjects switched from latanoprost (n=10) showed significant improvement in fluorescein staining score (P<0.05) as well as in IOP lowering (P<0.01). The subjects switched from travoprost (n=17) also showed significant improvement in fluorescein staining score (P<0.001), but without a significant change in IOP lowering. Conclusions: Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect, but also for its good corneal safety profile. | |||||
書誌情報 |
Journal of Ocular Pharmacology and Therapeutics 巻 30, 号 4, p. 340-345, 発行日 2014-05-01 |
|||||
出版者 | ||||||
出版者 | Mary Ann Liebert Inc. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 10807683 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 15577732 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1089/jop.2013.0132 | |||||
権利 | ||||||
権利情報 | This is a copy of an article published in the Journal of Ocular Pharmacology and Therapeutics c 2014 copyright Mary Ann Liebert, Inc.; Journal of Ocular Pharmacology and Therapeutics is available online at: http://online.liebertpub.com. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal of Ocular Pharmacology and Therapeutics, 30(4), pp.340-345; 2014 |